Notice Information
Notice Title
Services to deliver Onasemnogene abeparvovec/Zolgensma
Notice Description
NHS England is seeking to commission a service to deliver Onasemnogene abeparvovec/Zolgensma from four providers in England. It is currently anticipated that there may be one provider to cover the North of England, one to cover the Midlands, one to cover the South of England plus one other. The commissioner is by no means fixed on this geographical spread as the quality of the service provision is the most important factor.
Lot Information
Lot 1
Spinal muscular atrophy, or SMA, is a rare genetic disorder that causes muscle weakness and progressive loss of movement. It is most commonly caused by defects in the gene SMN1. Onasemnogene abeparvovec (Zolgensma, AveXis) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival motor neuron (SMN) protein, which is lacking or mutated in people with SMA. When injected, the vector is expected to carry the gene into the nerve cells, enabling production of sufficient amounts of SMN. It is administered intravenously. NHS England is seeking to commission a service to deliver Onasemnogene abeparvovec/Zolgensma from four providers in England. It is currently anticipated that there may be one provider to cover the North of England, one to cover the Midlands, one to cover the South of England plus one other. The commissioner is by no means fixed on this geographical spread as the quality of the service provision is the most important factor. As well as having a neuromuscular MDT and experience in treating children with SMA, the successful providers will need to have the capability to safely manage the product itself in line with it being classified as 'containment level 1' and ensure that all elements of the patient pathway (pre-treatment, during treatment and post-treatment) can be put into place. The providers will also be expected to operate as a national-MDT to ensure that eligible patients can be treated within appropriate timescales. This will involve regular meetings/calls to discuss the appropriate treatment of individual patients and to share information on capacity to treat patients. It is anticipated that the number of children requiring treatment each year is between 25 and 35, although this number may be subject to change, depending on the outcome of the NICE evaluation and, for example, if new-born screening for SMA was introduced. Novartis Gene Therapies is the company who produce this gene therapy and providers will be required to comply with the company's contractual documentation. This is currently in draft so providers will be expected to have contacted Novartis Gene Therapies prior to submitting a tender response to discuss their requirements in respect of providing a service to deliver Onasemnogene abeparvovec/Zolgensma. Given the significant amount of preparatory work that needs to be undertaken to deliver a gene therapy service, it is not feasible for commissioners and providers to wait until NICE has made its recommendation. To do so would risk the NHS not being ready to provide access within the timeframe set out in the Mandate requirements on NICE approved treatments and not being able to make the treatment available as soon as possible after the NICE decision has been made. Providers are therefore submitting bids to deliver a service 'at risk' and it may be the case that the product does not receive a positive NICE recommendation. Bidders are responsible for their own costs incurred throughout each stage of the Procurement process. Additional information: All bidders must complete the Qualification Questionnaire and Technical Questions.
Notice Details
Publication & Lifecycle
- Open Contracting ID
- ocds-h6vhtk-028f59
- Publication Source
- Find A Tender Service
- Latest Notice
- https://www.find-tender.service.gov.uk/Notice/014964-2021
- Current Stage
- Award
- All Stages
- Tender, Award
Procurement Classification
- Notice Type
- Tender Notice
- Procurement Type
- Standard
- Procurement Category
- Services
- Procurement Method
- Open
- Procurement Method Details
- Open procedure
- Tender Suitability
- Not specified
- Awardee Scale
- Large
Common Procurement Vocabulary (CPV)
- CPV Divisions
85 - Health and social work services
-
- CPV Codes
85000000 - Health and social work services
85100000 - Health services
85140000 - Miscellaneous health services
Notice Value(s)
- Tender Value
- £6,000,000 £1M-£10M
- Lots Value
- Not specified
- Awards Value
- Not specified
- Contracts Value
- £6,000,000 £1M-£10M
Notice Dates
- Publication Date
- 30 Jun 20214 years ago
- Submission Deadline
- 8 Mar 2021Expired
- Future Notice Date
- Not specified
- Award Date
- 27 May 20214 years ago
- Contract Period
- Not specified - Not specified
- Recurrence
- Not specified
Notice Status
- Tender Status
- Complete
- Lots Status
- Cancelled
- Awards Status
- Active
- Contracts Status
- Active
Buyer & Supplier
Contracting Authority (Buyer)
- Main Buyer
- NHS ENGLAND - SPECIALISED COMMISSIONING
- Contact Name
- Available with D3 Tenders Premium →
- Contact Email
- Available with D3 Tenders Premium →
- Contact Phone
- Available with D3 Tenders Premium →
Buyer Location
- Locality
- LONDON
- Postcode
- SE1 6LH
- Post Town
- South East London
- Country
- England
-
- Major Region (ITL 1)
- TLI London
- Basic Region (ITL 2)
- TLI4 Inner London - East
- Small Region (ITL 3)
- TLI44 Lewisham and Southwark
- Delivery Location
- Not specified
-
- Local Authority
- Southwark
- Electoral Ward
- St George's
- Westminster Constituency
- Bermondsey and Old Southwark
Further Information
Open Contracting Data Standard (OCDS)
View full OCDS Record for this contracting process
The Open Contracting Data Standard (OCDS) is a framework designed to increase transparency and access to public procurement data in the public sector. It is widely used by governments and organisations worldwide to report on procurement processes and contracts.
{
"tag": [
"compiled"
],
"id": "ocds-h6vhtk-028f59-2021-06-30T15:23:37+01:00",
"date": "2021-06-30T15:23:37+01:00",
"ocid": "ocds-h6vhtk-028f59",
"initiationType": "tender",
"tender": {
"id": "ocds-h6vhtk-028f59",
"legalBasis": {
"id": "32014L0024",
"scheme": "CELEX"
},
"title": "Services to deliver Onasemnogene abeparvovec/Zolgensma",
"status": "complete",
"classification": {
"scheme": "CPV",
"id": "85000000",
"description": "Health and social work services"
},
"mainProcurementCategory": "services",
"description": "NHS England is seeking to commission a service to deliver Onasemnogene abeparvovec/Zolgensma from four providers in England. It is currently anticipated that there may be one provider to cover the North of England, one to cover the Midlands, one to cover the South of England plus one other. The commissioner is by no means fixed on this geographical spread as the quality of the service provision is the most important factor.",
"value": {
"amount": 6000000,
"currency": "GBP"
},
"lots": [
{
"id": "1",
"description": "Spinal muscular atrophy, or SMA, is a rare genetic disorder that causes muscle weakness and progressive loss of movement. It is most commonly caused by defects in the gene SMN1. Onasemnogene abeparvovec (Zolgensma, AveXis) is a single-use gene replacement therapy made of a viral vector that has been modified to contain the primary gene for the human survival motor neuron (SMN) protein, which is lacking or mutated in people with SMA. When injected, the vector is expected to carry the gene into the nerve cells, enabling production of sufficient amounts of SMN. It is administered intravenously. NHS England is seeking to commission a service to deliver Onasemnogene abeparvovec/Zolgensma from four providers in England. It is currently anticipated that there may be one provider to cover the North of England, one to cover the Midlands, one to cover the South of England plus one other. The commissioner is by no means fixed on this geographical spread as the quality of the service provision is the most important factor. As well as having a neuromuscular MDT and experience in treating children with SMA, the successful providers will need to have the capability to safely manage the product itself in line with it being classified as 'containment level 1' and ensure that all elements of the patient pathway (pre-treatment, during treatment and post-treatment) can be put into place. The providers will also be expected to operate as a national-MDT to ensure that eligible patients can be treated within appropriate timescales. This will involve regular meetings/calls to discuss the appropriate treatment of individual patients and to share information on capacity to treat patients. It is anticipated that the number of children requiring treatment each year is between 25 and 35, although this number may be subject to change, depending on the outcome of the NICE evaluation and, for example, if new-born screening for SMA was introduced. Novartis Gene Therapies is the company who produce this gene therapy and providers will be required to comply with the company's contractual documentation. This is currently in draft so providers will be expected to have contacted Novartis Gene Therapies prior to submitting a tender response to discuss their requirements in respect of providing a service to deliver Onasemnogene abeparvovec/Zolgensma. Given the significant amount of preparatory work that needs to be undertaken to deliver a gene therapy service, it is not feasible for commissioners and providers to wait until NICE has made its recommendation. To do so would risk the NHS not being ready to provide access within the timeframe set out in the Mandate requirements on NICE approved treatments and not being able to make the treatment available as soon as possible after the NICE decision has been made. Providers are therefore submitting bids to deliver a service 'at risk' and it may be the case that the product does not receive a positive NICE recommendation. Bidders are responsible for their own costs incurred throughout each stage of the Procurement process. Additional information: All bidders must complete the Qualification Questionnaire and Technical Questions.",
"contractPeriod": {
"durationInDays": 1800
},
"status": "cancelled",
"awardCriteria": {
"criteria": [
{
"name": "Quality",
"type": "quality",
"description": "100"
},
{
"type": "price",
"description": "0"
}
]
},
"hasOptions": false
}
],
"items": [
{
"id": "1",
"additionalClassifications": [
{
"scheme": "CPV",
"id": "85100000",
"description": "Health services"
},
{
"scheme": "CPV",
"id": "85140000",
"description": "Miscellaneous health services"
}
],
"deliveryAddresses": [
{
"region": "UK"
},
{
"region": "UK"
}
],
"relatedLot": "1"
}
],
"submissionMethod": [
"electronicSubmission",
"written"
],
"submissionMethodDetails": "https://uk.eu-supply.com/app/rfq/rwlentrance_s.asp?PID=36403&B=AGCSU",
"otherRequirements": {
"reductionCriteria": "As detailed within the ITT documents"
},
"procurementMethod": "open",
"procurementMethodDetails": "Open procedure",
"tenderPeriod": {
"endDate": "2021-03-08T12:00:00Z"
},
"submissionTerms": {
"languages": [
"en"
]
},
"coveredBy": [
"GPA"
]
},
"parties": [
{
"id": "GB-FTS-4052",
"name": "NHS England - Specialised Commissioning",
"identifier": {
"legalName": "NHS England - Specialised Commissioning",
"id": "na"
},
"address": {
"streetAddress": "80 London Road",
"locality": "London",
"region": "UK",
"postalCode": "SE1 6LH",
"countryName": "United Kingdom"
},
"contactPoint": {
"name": "Anna Salt",
"email": "anna.salt@nhs.net",
"url": "https://uk.eu-supply.com/app/rfq/rwlentrance_s.asp?PID=36403&B=AGCSU"
},
"roles": [
"buyer"
],
"details": {
"url": "http://www.england.nhs.uk",
"buyerProfile": "https://uk.eu-supply.com/ctm/Company/CompanyInformation/Index/68205",
"classifications": [
{
"scheme": "TED_CA_TYPE",
"id": "BODY_PUBLIC",
"description": "Body governed by public law"
},
{
"scheme": "COFOG",
"id": "07",
"description": "Health"
}
]
}
},
{
"id": "GB-FTS-4053",
"name": "Arden & GEM Commissioning Support Unit",
"identifier": {
"legalName": "Arden & GEM Commissioning Support Unit"
},
"address": {
"streetAddress": "2nd Floor Cardinal Square, 10 Nottingham Road",
"locality": "Derby",
"postalCode": "DE1 3QT",
"countryName": "United Kingdom"
},
"roles": [
"reviewBody",
"mediationBody",
"reviewContactPoint"
]
},
{
"id": "GB-FTS-21062",
"name": "Manchester University Hospitals Foundation Trust",
"identifier": {
"legalName": "Manchester University Hospitals Foundation Trust"
},
"address": {
"locality": "Manchester",
"region": "UKD",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-21063",
"name": "Guy's and St Thomas' NHS Foundation Trust",
"identifier": {
"legalName": "Guy's and St Thomas' NHS Foundation Trust"
},
"address": {
"locality": "London",
"region": "UKI",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-3327",
"name": "Sheffield Children's NHS Foundation Trust",
"identifier": {
"legalName": "Sheffield Children's NHS Foundation Trust"
},
"address": {
"locality": "Sheffield",
"region": "UKE",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
},
{
"id": "GB-FTS-21064",
"name": "University Hospitals Bristol and Weston NHS Foundation Trust",
"identifier": {
"legalName": "University Hospitals Bristol and Weston NHS Foundation Trust"
},
"address": {
"locality": "Bristol",
"region": "UKK",
"countryName": "United Kingdom"
},
"roles": [
"supplier"
],
"details": {
"scale": "large"
}
}
],
"buyer": {
"id": "GB-FTS-4052",
"name": "NHS England - Specialised Commissioning"
},
"language": "en",
"awards": [
{
"id": "014964-2021-1-1",
"relatedLots": [
"1"
],
"title": "Services to deliver Onasemnogene abeparvovec/Zolgensma",
"status": "active",
"suppliers": [
{
"id": "GB-FTS-21062",
"name": "Manchester University Hospitals Foundation Trust"
},
{
"id": "GB-FTS-21063",
"name": "Guy's and St Thomas' NHS Foundation Trust"
},
{
"id": "GB-FTS-3327",
"name": "Sheffield Children's NHS Foundation Trust"
},
{
"id": "GB-FTS-21064",
"name": "University Hospitals Bristol and Weston NHS Foundation Trust"
}
]
}
],
"contracts": [
{
"id": "014964-2021-1-1",
"awardID": "014964-2021-1-1",
"title": "Services to deliver Onasemnogene abeparvovec/Zolgensma",
"status": "active",
"value": {
"amount": 6000000,
"currency": "GBP"
},
"dateSigned": "2021-05-28T00:00:00+01:00"
}
],
"bids": {
"statistics": [
{
"id": "1",
"measure": "bids",
"relatedLot": "1",
"value": 11
}
]
}
}